Primary Objective:

Assess the comparative safety and tolerability of two SAR153191 (REGN88) drug products after a single dose administration in rheumatoid arthritis patients.

Secondary Objective:

Assess the comparative pharmacokinetic profiles of the two SAR153191 (REGN88) drug products after a single dose administration in rheumatoid arthritis patients.

Read more: http://www.clinicaltrials.gov/ct2/show/NCT01328522?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30